Resultados de búsqueda - Mark M. Awad

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients por F. Stephen Hodi, Pasi A. Janne, Mark M. Awad, Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, Anika E. Adeni, Hiroto Hatabu

Enlace del recurso

Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study por Mark M. Awad, Yvan Le Bruchec, Brian Lu, Jason Ye, Julie Ann Miller, Patrick H. Lizotte, Megan E. Cavanaugh, Amanda J. Rode, Calin Dan Dumitru, Alexander Spira

Enlace del recurso

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC por Mariano Severgnini, Biagio Ricciuti, Alissa Keegan, Padric Garden, Limor Cohen, Reiko Nishihara, Anika Adeni, Cloud Paweletz, Julianna Supplee, Pasi A Jänne, Mark M Awad, David R Walt

Enlace del recurso

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers por Taek-Chin Cheong, Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti, Joao V. Alessi, Alessandro Di Federico, Mark M. Awad, Maria K. Lehtinen, Marian H. Harris, Roberto Chiarle

Enlace del recurso

Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer por Xinan Wang, Kangcheng Hou, Biagio Ricciuti, Joao V. Alessi, Xihao Li, Federica Pecci, Rounak Dey, Jia Luo, Mark M. Awad, Alexander Gusev, Xihong Lin, Bruce E. Johnson, David C. Christiani

Enlace del recurso

Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology por Elio Adib, Amin H. Nassar, Sarah Abou Alaiwi, Stefan Groha, Elie W. Akl, Lynette M. Sholl, Kesi S. Michael, Mark M. Awad, Pasi A. Jӓnne, Alexander Gusev, David J. Kwiatkowski

Enlace del recurso

Graph neural network modeling of spatial tumor-immune interactions identifies prognostic cellular niches in non‑small cell lung cancer por Katharina V. Hoebel, James R. Lindsay, Jennifer Altreuter, Joao V. Alessi, Jason L. Weirather, Ian Dryg, Anita Giobbie-Hurder, Zhirou Li, Kun-Hsing Yu, Mark M. Awad, Scott J. Rodig, William Lotter

Enlace del recurso

Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer por Daniel Reinhorn, MD, Jonathan Kuten, MD, MHA, Isabel Preeshagul, DO, MBS, Juliana Eng, MD, Kenneth Ng, MD, Alexander Drilon, MD, Jamie Chaft, MD, Fernando C. Santini, MD, Mark M. Awad, MD, PhD

Enlace del recurso

192 Clinicopathologic, genomic and immunophenotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma por Mizuki Nishino, Biagio Ricciuti, Scott J Rodig, Joao V Alessi, Jia Luo, Mark M Awad, Bruce E Johnson, Federica Pecci, Alessandro Di Federico, Malini M Gandhi, Lynette M Sholl, Maisam Makarem, Emma Voligny, Tom Nguyen, Danielle Haradon

Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings por Benjamin Izar, Justin F Gainor, Mark M Awad, Codruta Chiuzan, Anjali Saqi, Catherine A Shu, Katja Schulze, Brian S Henick, Naiyer A Rizvi, Samyukta Mallick, Yohanna Georgis, Peter D Koch, Stephanie Izard, Robert F Garofano, Cheryl V Wong, Jessica Grindheim, Joshua R Sonett, Alison M Taylor

Enlace del recurso

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer por Biagio Ricciuti, Joao V Alessi, Mark M Awad, Arielle Elkrief, Jamie E Chaft, Bruce E Johnson, Xinan Wang, Allison L Richards, Federica Pecci, Alessandro Di Federico, Adam J Schoenfeld, Malini M Gandhi, Adam Price, Emily S Lebow, Patricia Mae G Santos, Maria Thor, Andreas Rimner, Daniel R Gomez, Narek Shaverdian

Enlace del recurso

PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief Report por Elio Adib, MD, Amin H. Nassar, MD, Elias Bou Farhat, MD, Shyam K. Tanguturi, MD, Rifaquat M. Rahman, MD, Daphne A. Haas-Kogan, MD, MBA, Wenya Linda Bi, MD, PhD, Omar Arnaout, MD, Patrick Y. Wen, MD, David J. Kwiatkowski, MD, PhD, Mark M. Awad, MD, PhD, Ayal A. Aizer, MD

Enlace del recurso

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade por Marie-Julie Nokin, Alessia Mira, Enrico Patrucco, Biagio Ricciuti, Sophie Cousin, Isabelle Soubeyran, Sonia San José, Serena Peirone, Livia Caizzi, Sandra Vietti Michelina, Aurelien Bourdon, Xinan Wang, Daniel Alvarez-Villanueva, María Martínez-Iniesta, August Vidal, Telmo Rodrigues, Carmen García-Macías, Mark M. Awad, Ernest Nadal, Alberto Villanueva, Antoine Italiano, Matteo Cereda, David Santamaría, Chiara Ambrogio

Enlace del recurso

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations por James Artingstall, Alex Friedlaender, Alfredo Addeo, Judith Cave, Massimo Di Maio, Samuel Chan, Alessio Cortellini, Marcello Tiseo, Biagio Ricciuti, Francesco Facchinetti, Benjamin Besse, Joao V Alessi, Mark M Awad, David J Pinato, Giuseppe L Banna, Giuseppe Lamberti, Margarita Majem, Frank Aboubakar Nana, Charles Comins, Thomas Newsom-Davis, Victor R Vaz, Laura Mezquita, Davide Soldato, Filippo G Dall’Olio, Sethupathi Muthuramalingam, Aida Piedra, Elisa Andrini, Teresa Gorría, Delphine Hoton, Lacroix Valerie, Andrea Caglio, Hayley McKenzie, Joanne S Evans, Antonio D'Alessio, Claudia A M Fulgenzi

Enlace del recurso

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC por Hye Ryun Kim, MD, PhD, Mark M. Awad, MD, PhD, Alejandro Navarro, MD, Maya Gottfried, MD, Solange Peters, MD, PhD, Tibor Csőszi, MD, Parneet K. Cheema, MD, Delvys Rodriguez-Abreu, MD, PhD, Mirjana Wollner, MD, James Chih-Hsin Yang, MD, PhD, Julien Mazieres, MD, PhD, Francisco J. Orlandi, MD, Alexander Luft, MD, PhD, Mahmut Gümüş, MD, Terufumi Kato, MD, Gregory P. Kalemkerian, MD, Yiwen Luo, PhD, Melissa L. Santorelli, PhD, MPH, M. Catherine Pietanza, MD, Charles M. Rudin, MD, PhD

Enlace del recurso

218 Prospective spatial immune cell profiling identifies features of the tumor-immune microenvironment associated with genomic alterations and patient survival in a 2,023 patient p... por Sara M Tolaney, James Lindsay, Michael Manos, Biagio Ricciuti, Anita Giobbie-Hurder, Scott J Rodig, Joao V Alessi, Mark M Awad, Sandro Santagata, Bruce E Johnson, Glenn J Hanna, Elio Adib, Jason Weirather, Xinan Wang, Bijaya Sharma, Kathleen Pfaff, Kristen D Felt, William Lotter, Panagiotis Konstantinopoulos, Madison Turner, Federica Pecci, Emma L Welsh, Stephanie M Jones, Jennifer O Altreuter, Ian D Dryg, Alessandro Di Federico, Malini M Gandhi, Sabrina J Chan, Marta Holovatska, Melissa E Hughes, O’Meara Tess A, Neal I Lindeman, Jennifer Curtis, Peter K Sorger, Ethan Cerami, Lynette M Sholl, Jonathan A Novak

Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors por Alissa J. Cooper, MD, Andrea Arfe, PhD, Biagio Ricciuti, MD, Andréanne Gagné, MD, PhD, Lynette M. Sholl, MD, Alessandro Di Federico, MD, Mark M. Awad, MD, PhD, Mihaela Aldea, MD, PhD, Maria Rosa Ghigna, MD, Miruna Grecea, MD, Phoebe Clark, MS, Jamie E. Chaft, MD, Mark G. Kris, MD, Gregory J. Riely, MD, Charles M. Rudin, MD, PhD, Ibiayi Dagogo-Jack, MD, Mari Mino-Kenudson, MD, Lingzhi Hong, MD, PhD, Neda Kalhor, MD, Natalie Vokes, MD, Anita Bowman, MS, Soo-Ryum Yang, MD, Natasha Rekhtman, MD, PhD, Adam J. Schoenfeld, MD

Enlace del recurso

Sotorasib in Advanced KRAS G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS Metastases por Silvia Novello, MD, PhD, Natalie Maimon Rabinovich, MD, Jin-Yuan Shih, MD, PhD, Giacomo Pelizzari, MD, James Stevenson, MD, Margarita Majem, MD, PhD, Carlos Gil Ferreira, MD, William J. Petty, MD, Edurne Arriola, MD, PhD, Nicolas Castagneris, MD, Javier De Castro, MD, PhD, Igor Morbeck, MD, MSc, MBA, Jessica Bauman, MD, Luca Toschi, MD, Alona Zer, MD, Giulio Metro, MD, Sujith Kalmadi, MD, Aitor Azkarate Martinez, MD, Hamed Al Husaini, MD, Alison R. Meloni, PhD, Chidozie Nduka, PhD, Christine Ardito-Abraham, PhD, Caihong Xia, PhD, Mark M. Awad, MD, PhD

Enlace del recurso

Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With Fi... por Biagio Ricciuti, MD, PhD, Arielle Elkrief, MD, Jessica Lin, MD, Jianjun Zhang, MD, Joao V. Alessi, MD, Giuseppe Lamberti, MD, PhD, Malini Gandhi, MD, Alessandro Di Federico, MD, Federica Pecci, MD, Xinan Wang, PhD, Maisam Makarem, MD, PhD, Cassio Murilo Hidalgo Filho, MD, Teresa Gorria, MD, Arushi Saini, BS, Cindy Pabon, MD, James Lindsay, PhD, Kathleen L. Pfaff, PhD, Emma L. Welsh, BS, Mizuki Nishino, MD, Lynette M. Sholl, MD, Scott Rodig, MD, Saadettin Kilickap, MD, Petra Rietschel, MD, Debra AG. McIntyre, PhD, Jean-Francois Pouliot, MD, Mehmet Altan, MD, Justin F. Gainor, MD, John V. Heymach, MD, Adam J. Schoenfeld, MD, Mark M. Awad, MD, PhD

Enlace del recurso